Sarcomeric α-actinins and their role in human muscle disease

Future Neurology

Volumn 4, Issue 6, 2009, Pages 731-743

  Houweling, Peter J ^a   North, Kathryn N ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

Author keywords

actinin 3; ACTN3; Disease modification; Intranuclear rod myopathy; Myofibrillar myopathy; Nemaline myopathy; Sarcomeric actinin; Skeletal muscle

Indexed keywords

ALPHA ACTININ; ALPHA ACTININ 1; ALPHA ACTININ 2; ALPHA ACTININ 3; ALPHA ACTININ 4;

ACTIN FILAMENT; CONGESTIVE CARDIOMYOPATHY; FOCAL GLOMERULOSCLEROSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITARY INCLUSION BODY MYOPATHY; HUMAN; INTRANUCLEAR ROD MYOPATHY; KNOCKOUT MOUSE; MUSCLE FUNCTION; MYOFIBRILLAR MYOPATHY; MYOPATHY; NEMALINE MYOPATHY; NEUROMUSCULAR DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SARCOMERE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

EID: 75249105983     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/fnl.09.60     Document Type: Review

References (118)

1. Blanchard A, Ohanian V, Critchley D: The structure and function of α-actinin. J. Muscle Res. Cell. Motil. 10, 280-289 (1989).
2. North KN, Yang N, Wattanasirichaigoon D et al.: A common nonsense mutation results in α-actinin-3 deficiency in the general population. Nat. Genet. 21, 353-354 (1999). ■■ First report of a common mutation in α-actinin-3 (ACTN3) in the general population.
3. Noegel A, Witke W, Schleicher M: Calcium-sensitive non-muscle α-actinin contains EF-hand structures and highly conserved regions. FEBS Lett. 221, 391-396 (1987).
4. Fyrberg E, Kelly M, Ball E et al.: Molecular genetics of Drosophila α-actinin: mutant alleles disrupt Z disc integrity and muscle insertions. J. Cell Biol. 110, 1999-2011 (1990).
5. Barstead RJ, Kleiman L, Waterston RH: Cloning, sequencing, and mapping of an α-actinin gene from the nematode Caenorhabditis elegans. Cell Motil. Cytoskeleton 20, 69-78 (1991).
6. Arimura C, Suzuki T, Yanagisawa M et al.: Primary structure of chicken skeletal muscle and fibroblast α-actinins deduced from cDNA sequences. Eur. J. Biochem. 177, 649-655 (1988).
7. Beggs AH, Byers TJ, Knoll JH et al.: Cloning and characterization of two human skeletal muscle α-actinin genes located on chromosomes 1 and 11. J. Biol. Chem. 267, 9281-9288 (1992).
8. MacArthur DG, North KN: A gene for speed? The evolution and function of α-actinin-3. Bioessays 26, 786-795 (2004). ■■ Comprehensive review of the evolution and role of α-actinin-3 in humans.
9. Honda K, Yamada T, Endo R et al.: Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J. Cell Biol. 140, 1383-1393 (1998).
10. Krakhmaleva IN, Shishkin SS, Shakhovskaia NI et al.: NP-detecting DNA technologies: solving problems of applied biochemistry. Prikl Biokhim. Mikrobiol. 41, 303-307 (2005).
11. Mills M, Yang N, Weinberger R et al.: Differential expression of the actin-binding proteins, α-actinin-2 and -3, in different species: implications for the evolution of functional redundancy. Hum. Mol. Genet. 10, 1335-1346 (2001). ■■ Detailed analysis of the expression of sarcomeric α-actinins.
12. Southby J, Gooding C, Smith CW: Polypyrimidine tract binding protein functions as a repressor to regulate alternative splicing of α-actinin mutally exclusive exons. Mol. Cell Biol. 19, 2699-2711 (1999).
13. Mukhina S, Wang YL, Murata-Hori M: α-actinin is required for tightly regulated remodeling of the actin cortical network during cytokinesis. Dev. Cell 13, 554-565 (2007).
14. Otey CA, Carpen O: α-actinin revisited: a fresh look at an old player. Cell Motil. Cytoskeleton 58, 104-111 (2004).
15. Ehler E, Gautel M: The sarcomere and sarcomerogenesis. Adv. Exp. Med. Biol. 642, 1-14 (2008).
16. North KN, Beggs AH: Deficiency of a skeletal muscle isoform of α-actinin (α-actinin-3) in merosin-positive congenital muscular dystrophy. Neuromuscul. Disord. 6, 229-235 (1996). ■■ First report of a mutation in ACTN3 not associated with a disease phenotype.
17. Sjoblom B, Salmazo A, Djinovic-Carugo K: α-actinin structure and regulation. Cell. Mol. Life Sci. 65, 2688-2701 (2008).
18. Kuhlman PA, Ellis J, Critchley DR et al.: The kinetics of the interaction between the actin-binding domain of α-actinin and F-actin. FEBS Lett. 339, 297-301 (1994).
19. Salmikangas P, Mykkanen OM, Gronholm M et al.: Myotilin, a novel sarcomeric protein with two Ig-like domains, is encoded by a candidate gene for limb-girdle muscular dystrophy. Hum. Mol. Genet. 8, 1329-1336 (1999).
20. Ohtsuka H, Yajima H, Maruyama K et al.: Binding of the N-terminal 63 kDa portion of connectin/titin to α-actinin as revealed by the yeast two-hybrid system. FEBS Lett. 401, 65-67 (1997).
21. Nave R, Furst DO, Weber K: Interaction of α-actinin and nebulin in vitro. Support for the existence of a fourth filament system in skeletal muscle. FEBS Lett. 269, 163-166 (1990).
22. Hance JE, Fu SY, Watkins SC et al.: α-actinin-2 is a new component of the dystrophin-glycoprotein complex. Arch. Biochem. Biophys. 365, 216-222 (1999).
23. Otey CA, Pavalko FM, Burridge K: An interaction between α-actinin and the β1 integrin subunit in vitro. J. Cell Biol. 111, 721-729 (1990).
24. Ervasti JM, Campbell KP: Membrane organization of the dystrophin-glycoprotein complex. Cell 66, 1121-1131 (1991).
25. Watkins SC, Cullen MJ, Hoffman EP et al.: Plasma membrane cytoskeleton of muscle: a fine structural analysis. Microsc Res Tech 48, 131-141 (2000).
26. Endo T, Masaki T: Differential expression and distribution of chicken skeletal- and smooth-muscle-type α-actinins during myogenesis in culture. J. Cell Biol. 99, 2322-2332 (1984).
27. Goffart S, Franko A, Clemen CS et al.: α-actinin 4 and BAT1 interaction with the cytochrome c promoter upon skeletal muscle differentiation. Curr. Genet. 49, 125-135 (2006).
28. Argov Z, Yarom R: Rimmed vacuole myopathy sparing the quadriceps. A unique disorder in Iranian Jews. J. Neurol. Sci. 64, 33-43 (1984).
29. Eisenberg I, Avidan N, Potikha T et al.: The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat. Genet. 29, 83-87 (2001).
30. Amsili S, Zer H, Hinderlich S et al.: UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) binds to α-actinin 1: novel pathways in skeletal muscle? PLoS ONE 3, E2477 (2008).
31. Malicdan MC, Noguchi S, Hayashi YK et al.: Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat. Med. 15, 690-695 (2009).
32. Keppler OT, Hinderlich S, Langner J et al.: UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. Science 284, 1372-1376 (1999).
33. Kaplan JM, Kim SH, North KN et al.: Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis. Nat. Genet. 24, 251-256 (2000).
34. Weins A, Kenlan P, Herbert S et al.: Mutational and biological analysis of α-actinin-4 in focal segmental glomerulosclerosis. J. Am. Soc. Nephrol. 16, 3694-3701 (2005).
35. Kos CH, Le TC, Sinha S et al.: Mice deficient in α-actinin-4 have severe glomerular disease. J. Clin. Invest. 111, 1683-1690 (2003).
36. Yao J, Le TC, Kos CH et al.: α-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. PLoS Biol 2, E167 (2004).
37. Menez J, Le Maux Chansac B, Dorothee G et al.: Mutant α-actinin-4 promotes tumorigenicity and regulates cell motility of a human lung carcinoma. Oncogene 23, 2630-2639 (2004).
38. Dec GW, Fuster V: Idiopathic dilated cardiomyopathy. N. Engl. J. Med. 331, 1564-1575 (1994).
39. Kamisago M, Sharma SD, DePalma SR et al.: Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N. Engl. J. Med. 343, 1688-1696 (2000). ■ Mutation in ACTN2 resulting in cardiomyopathy.
40. Chang AN, Potter JD: Sarcomeric protein mutations in dilated cardiomyopathy. Heart Fail. Rev. 10, 225-235 (2005).
41. Mohapatra B, Jimenez S, Lin JH et al.: Mutations in the muscle LIM protein and α-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol. Genet. Metab. 80, 207-215 (2003).
42. Sadler I, Crawford AW, Michelsen JW et al.: Zyxin and cCRP: two interactive LIM domain proteins associated with the cytoskeleton. J. Cell Biol. 119, 1573-1587 (1992).
43. Nix DA, Beckerle MC: Nuclear-cytoplasmic shuttling of the focal contact protein, zyxin: a potential mechanism for communication between sites of cell adhesion and the nucleus. J. Cell Biol. 138, 1139-1147 (1997).
44. Dubreuil RR: Structure and evolution of the actin crosslinking proteins. Bioessays 13, 219-226 (1991).
45. Roulier EM, Fyrberg C, Fyrberg E: Perturbations of Drosophila α-actinin cause muscle paralysis, weakness, and atrophy but do not confer obvious nonmuscle phenotypes. J. Cell Biol. 116, 911-922 (1992).
46. Macarthur DG, Seto JT, Chan S et al.: An Actn3 knockout mouse provides mechanistic insights into the association between α-actinin-3 deficiency and human athletic performance. Hum. Mol. Genet. 17(8), 1076-1086 (2008).
47. MacArthur DG, Seto JT, Raftery JM et al.: Loss of ACTN3 gene function alters mouse muscle metabolism and shows evidence of positive selection in humans. Nat. Genet. 39, 1261-1265 (2007). ■ ACTN3-knockout mouse phenotype and evolutionary data.
48. Nowak KJ, Wattanasirichaigoon D, Goebel HH et al.: Mutations in the skeletal muscle α-actin gene in patients with actin myopathy and nemaline myopathy. Nat. Genet. 23, 208-212 (1999).
49. Jennekens FG, Roord JJ, Veldman H et al.: Congenital nemaline myopathy. I. Defective organization of α-actinin is restricted to muscle. Muscle Nerve 6, 61-68 (1983).
50. Ryan MM, Ilkovski B, Strickland CD et al.: Clinical course correlates poorly with muscle pathology in nemaline myopathy. Neurology 60, 665-673 (2003).
51. Ryan MM, Schnell C, Strickland CD et al.: Nemaline myopathy: a clinical study of 143 cases. Ann. Neurol. 50, 312-320 (2001).
52. North K: Congenital myopathies. In: Myology. Engel A, Franzini-Armstrong C (Eds). McGraw Hill, NY, USA, 1473-1534 (2004).
53. Domazetovska A, Ilkovski B, Cooper ST et al.: Mechanisms underlying intranuclear rod formation. Brain 130, 3275-3284 (2007).
54. Lin Z, Hijikata T, Zhang Z et al.: Dispensability of the actin-binding site and spectrin repeats for targeting sarcomeric α-actinin into maturing Z bands in vivo: implications for in vitro binding studies. Dev. Biol. 199, 291-308 (1998).
55. Schultheiss T, Choi J, Lin ZX et al.: A sarcomeric α-actinin truncated at the carboxyl end induces the breakdown of stress fibers in PtK2 cells and the formation of nemaline-like bodies and breakdown of myofibrils in myotubes. Proc. Natl Acad. Sci. USA 89, 9282-9286 (1992).
56. Zhang ZQ, Bish LT, Holtzer H et al.: Sarcomeric-α-actinin defective in vinculin-binding causes Z-line expansion and nemaline-like body formation in cultured chick myotubes. Exp. Cell Res. 315, 748-759 (2009). ■ Possible role of defective α-actinin binding in nemaline myopathy pathogenesis.
57. Goebel HH, Warlo I: Nemaline myopathy with intranuclear rods - intranuclear rod myopathy. Neuromuscul. Disord. 7, 13-19 (1997).
58. Hutchinson DO, Charlton A, Laing NG et al.: Autosomal dominant nemaline myopathy with intranuclear rods due to mutation of the skeletal muscle ACTA1 gene: clinical and pathological variability within a kindred. Neuromuscul. Disord. 16, 113-121 (2006).
59. Agrawal PB, Strickland CD, Midgett C et al.: Heterogeneity of nemaline myopathy cases with skeletal muscle α-actin gene mutations. Ann. Neurol. 56, 86-96 (2004).
60. Sparrow JC, Nowak KJ, Durling HJ et al.: Muscle disease caused by mutations in the skeletal muscle α-actin gene (ACTA1). Neuromuscul. Disord. 13, 519-531 (2003).
61. North KN, Laing NG: Skeletal muscle α-actin diseases. Adv. Exp. Med. Biol. 642, 15-27 (2008).
62. Young KG, Kothary R: Spectrin repeat proteins in the nucleus. Bioessays 27, 144-152 (2005).
63. Domazetovska A, Ilkovski B, Kumar V et al.: Intranuclear rod myopathy: molecular pathogenesis and mechanisms of weakness. Ann. Neurol. 62, 597-608 (2007).
64. Goldfarb LG, Park KY, Cervenakova L et al.: Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat. Genet. 19, 402-403 (1998).
65. Vicart P, Caron A, Guicheney P et al.: A missense mutation in the αB-crystallin chaperone gene causes a desmin-related myopathy. Nat. Genet. 20, 92-95 (1998).
66. Vorgerd M, van der Ven PF, Bruchertseifer V et al.: A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. Am. J. Hum. Genet. 77, 297-304 (2005).
67. Quinzii CM, Vu TH, Min KC et al.: X-linked dominant scapuloperoneal myopathy is due to a mutation in the gene encoding four-and-a-half-LIM protein 1. Am. J. Hum. Genet. 82, 208-213 (2008).
68. Selcen D, Engel AG: Mutations in myotilin cause myofibrillar myopathy. Neurology 62, 1363-1371 (2004).
69. Selcen D, Engel AG: Mutations in ZASP define a novel form of muscular dystrophy in humans. Ann. Neurol. 57, 269-276 (2005).
70. Selcen D, Muntoni F, Burton BK et al.: Mutation in BAG3 causes severe dominant childhood muscular dystrophy. Ann. Neurol. 65, 83-89 (2009).
71. Claeys KG, van der Ven PF, Behin A et al.: Differential involvement of sarcomeric proteins in myofibrillar myopathies: a morphological and immunohistochemical study. Acta Neuropathol 117, 293-307 (2009). ■ Recent review on the role of sarcomeric proteins in myofibrillar myopathies.
72. Selcen D: Myofibrillar myopathies. Curr. Opin. Neurol. 21, 585-589 (2008).
73. Nakano S, Engel AG, Akiguchi I et al.: Myofibrillar myopathy. III. Abnormal expression of cyclin-dependent kinases and nuclear proteins. J. Neuropathol. Exp. Neurol. 56, 850-856 (1997).
74. Reimann J, Kunz WS, Vielhaber S et al.: Mitochondrial dysfunction in myofibrillar myopathy. Neuropathol. Appl. Neurobiol. 29, 45-51 (2003).
75. Schroder R, Goudeau B, Simon MC et al.: On noxious desmin: functional effects of a novel heterozygous desmin insertion mutation on the extrasarcomeric desmin cytoskeleton and mitochondria. Hum. Mol. Genet. 12, 657-669 (2003).
76. Milner DJ, Mavroidis M, Weisleder N et al.: Desmin cytoskeleton linked to muscle mitochondrial distribution and respiratory function. J. Cell Biol. 150, 1283-1298 (2000).
77. Selcen D, Ohno K, Engel AG: Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. Brain 127, 439-451 (2004).
78. Claeys KG, Fardeau M, Schroder R et al.: Electron microscopy in myofibrillar myopathies reveals clues to the mutated gene. Neuromuscul. Disord. 18, 656-666 (2008).
79. Selcen D, Engel AG: Myofibrillar myopathy. In: Myology. Engel A, Franzini-Armstrong C (Eds). McGraw Hill, NY, USA 1187-1202 (2004).
80. Hauser MA, Horrigan SK, Salmikangas P et al.: Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum. Mol. Genet. 9, 2141-2147 (2000).
81. Salmikangas P, van der Ven PF, Lalowski M et al.: Myotilin, the limb-girdle muscular dystrophy 1A (LGMD1A) protein, cross-links actin filaments and controls sarcomere assembly. Hum. Mol. Genet. 12, 189-203 (2003). ■ Sarcomeric α-actinin associated with myotilin.
82. Yang N, MacArthur DG, Gulbin JP et al.: ACTN3 genotype is associated with human elite athletic performance. Am. J. Hum. Genet. 73, 627-631 (2003). ■■ First report of α-actinin-3-null polymorphism (R577X) influencing muscle performance in elite Australian athletes.
83. Druzhevskaya AM, Ahmetov, II, Astratenkova IV et al.: Association of the ACTN3 R577X polymorphism with power athlete status in Russians. Eur. J. Appl. Physiol. 103, 631-634 (2008).
84. Niemi AK, Majamaa K: Mitochondrial DNA and ACTN3 genotypes in Finnish elite endurance and sprint athletes. Eur. J. Hum. Genet. 13, 965-969 (2005).
85. Papadimitriou ID, Papadopoulos C, Kouvatsi A et al.: The ACTN3 gene in elite Greek track and field athletes. Int. J. Sports Med. 29, 352-355 (2008).
86. Roth SM, Walsh S, Liu D et al.: The ACTN3 R577X nonsense allele is under-represented in elite-level strength athletes. Eur. J. Hum. Genet. 16, 391-394 (2008).
87. Santiago C, Gonzalez-Freire M, Serratosa L et al.: ACTN3 genotype in professional soccer players. Br. J. Sports Med. 42, 71-73 (2008).
88. Eynon N, Duarte JA, Oliveira J et al.: ACTN3 R577X polymorphism and Israeli top-level athletes. Int. J. Sports Med. (2009).
89. Clarkson PM, Hoffman EP, Zambraski E et al.: ACTN3 and MLCK genotype associations with exertional muscle damage. J. Appl. Physiol. 99, 564-569 (2005).
90. Moran CN, Yang N, Bailey ME et al.: Association analysis of the ACTN3 R577X polymorphism and complex quantitative body composition and performance phenotypes in adolescent Greeks. Eur. J. Hum. Genet. 15, 88-93 (2007).
91. Clarkson PM, Devaney JM, Gordish-Dressman H et al.: ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. J. Appl. Physiol. 99, 154-163 (2005).
92. Delmonico MJ, Kostek MC, Doldo NA et al.: α-actinin-3 (ACTN3) R577X polymorphism influences knee extensor peak power response to strength training in older men and women. J. Gerontol. A Biol. Sci. Med. Sci. 62, 206-212 (2007).
93. Vincent B, De Bock K, Ramaekers M et al.: The ACTN3 (R577X) genotype is associated with fiber type distribution. Physiol. Genomics 32(1), 58-63 (2007).
94. MacArthur DG, North KN: ACTN3: a genetic influence on muscle function and athletic performance. Exerc. Sport Sci. Rev. 35, 30-34 (2007).
95. Chan S, Seto JT, MacArthur DG et al.: A gene for speed: contractile properties of isolated whole EDL muscle from an α-actinin-3 knockout mouse. Am. J. Physiol. Cell Physiol. 295, C897-C904 (2008).
96. Lucia A, Gomez-Gallego F, Santiago C et al.: The 577X allele of the ACTN3 gene is associated with improved exercise capacity in women with McArdle's disease. Neuromuscul. Disord. 17, 603-610 (2007). ■■ First report of ACTN3 genotype influencing disease severity in the metabolic disorder McArdle's disease.
97. Tsujino S, Shanske S, DiMauro S: Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle's disease). N. Engl. J. Med. 329, 241-245 (1993).
98. Li HH, Kedar V, Zhang C et al.: Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J. Clin. Invest. 114, 1058-1071 (2004).
99. Papa I, Astier C, Kwiatek O et al.: α actinin-CapZ, an anchoring complex for thin filaments in Z-line. J. Muscle Res. Cell. Motil. 20, 187-197 (1999).
100. Rakus D, Pasek M, Krotkiewski H et al.: Interaction between muscle aldolase and muscle fructose 1,6-bisphosphatase results in the substrate channeling. Biochemistry 43, 14948-14957 (2004).
101. Gizak A, Rakus D, Dzugaj A: Immunohistochemical localization of human fructose-1,6-bisphosphatase in subcellular structures of myocytes. Histol. Histopathol. 18, 135-142 (2003).
102. Chowrashi P, Mittal B, Sanger JM et al.: Amorphin is phosphorylase; phosphorylase is an α-actinin-binding protein. Cell Motil. Cytoskeleton 53, 125-135 (2002).
103. Lane RD, Hegazy MG, Reimann EM: Subcellular localization of glycogen synthase with monoclonal antibodies. Biochem. Int. 18, 961-970 (1989).
104. Shibasaki F, Fukami K, Fukui Y et al.: Phosphatidylinositol 3-kinase binds to α-actinin through the p85 subunit. Biochem. J. 302(Pt 2), 551-557 (1994).
105. Pashmforoush M, Pomies P, Peterson KL et al.: Adult mice deficient in actinin-associated LIM-domain protein reveal a developmental pathway for right ventricular cardiomyopathy. Nat. Med. 7, 591-597 (2001).
106. Au Y, Atkinson RA, Guerrini R et al.: Solution structure of ZASP PDZ domain; implications for sarcomere ultrastructure and enigma family redundancy. Structure 12, 611-622 (2004).
107. Faulkner G, Pallavicini A, Formentin E et al.: ZASP: a new Z-band alternatively spliced PDZ-motif protein. J. Cell Biol. 146, 465-475 (1999).
108. Frey N, Olson EN: Calsarcin-3, a novel skeletal muscle-specific member of the calsarcin family, interacts with multiple Z-disc proteins. J. Biol. Chem. 277, 13998-14004 (2002).
109. Frey N, Richardson JA, Olson EN: Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc. Natl Acad. Sci. USA 97, 14632-14637 (2000).
110. 2+ channel by the actin-binding proteins α-actinin and dystrophin. Am. J. Physiol. Cell Physiol. 282, C1502-C1511 (2002).
111. Maruoka ND, Steele DF, Au BP et al.: α-actinin-2 couples to cardiac Kv1.5 channels, regulating current density and channel localization in HEK cells. FEBS Lett. 473, 188-194 (2000).
112. Cukovic D, Lu GW, Wible B et al.: A discrete amino terminal domain of Kv1.5 and Kv1.4 potassium channels interacts with the spectrin repeats of α-actinin-2. FEBS Lett. 498, 87-92 (2001).
113. Wyszynski M, Lin J, Rao A et al.: Competitive binding of α-actinin and calmodulin to the NMDA receptor. Nature 385, 439-442 (1997).
114. Freeman JL, Pitcher JA, Li X et al.: α-actinin is a potent regulator of G protein-coupled receptor kinase activity and substrate specificity in vitro. FEBS Lett. 473, 280-284 (2000).
115. Park JB, Kim JH, Kim Y et al.: Cardiac phospholipase D2 localizes to sarcolemmal membranes and is inhibited by α-actinin in an ADP-ribosylation factor-reversible manner. J. Biol. Chem. 275, 21295-21301 (2000).
116. Mukai H, Toshimori M, Shibata H et al.: Interaction of PKN with α-actinin. J. Biol. Chem. 272, 4740-6 (1997).
117. Arber S, Halder G, Caroni P: Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation. Cell 79, 221-231 (1994).
118. Crawford AW, Michelsen JW, Beckerle MC: An interaction between zyxin and α-actinin. J. Cell Biol. 116, 1381-1393 (1992).